In addition, oral insulin, by being absorbed into the hepatic portal circulation, mimics the physiological route of insulin delivery to the liver, thereby reducing the systemic hyperinsulinemia associated with the subcutaneous injection that delivers insulin to the peripheral circulation, and with the potential to minimize risk for hypoglycemia and improve metabolic control.2 This evidence concerns the gene INS and hyperinsulinism.